AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2316233 — intervention group
Group type: COMPARATOR
Intervention: Quinidine gluconate (648 mg) without aluminum hydroxide gel
Number of subjects: 8
Study 341313 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (0.5 mg/kg)
Number of subjects: 14
Study 341313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 30630371 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Number of subjects: 120
Study 30630371 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 120
Study 30630371 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril + Vildagliptin
Number of subjects: 120
Study 30630371 — intervention group
Group type: COMPARATOR
Intervention: Captopril + Metformin
Number of subjects: 120
Study 29960288 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiaoshen Kaiqiao acupuncture therapy and placebo starch tablets treatment
Number of subjects: 58
Study 29960288 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine tablets and body acupuncture treatment
Number of subjects: 58
Study 29960288 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiaoshen Kaiqiao acupuncture therapy
Number of subjects: 58
Study 25466703 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (6‐mg gum) + MAO‐A inhibition (moclobemide 75 mg)
Number of subjects: 24
Study 25466703 — intervention group
Group type: COMPARATOR
Intervention: Nicotine (6‐mg gum)
Number of subjects: 24
Study 25466703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 23439759 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 20 mg
Number of subjects: 48
Study 23439759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 20981577 — intervention group
Group type: EXPERIMENTAL
Intervention: Looking ≥ 5 years older than actual age
Number of subjects: 126
Study 20981577 — intervention group
Group type: EXPERIMENTAL
Intervention: Looking ≥ 10 years older than actual age
Number of subjects: 126
Study 18978029 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional rTMS (0.5 Hz)
Number of subjects: 22
Study 18978029 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional rTMS (10 Hz)
Number of subjects: 22
Study 18978029 — intervention group
Group type: EXPERIMENTAL
Intervention: Theta burst stimulation (cTBS)
Number of subjects: 22
Study 18978029 — intervention group
Group type: EXPERIMENTAL
Intervention: Theta burst stimulation (iTBS)
Number of subjects: 22
Study 18978029 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 22
Study 18978029 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor training (days 1 to 4)
Number of subjects: 22
Study 17553226 — intervention group
Group type: EXPERIMENTAL
Intervention: MSS‐HTA (multiple site‐specific heteroduplex tracking assay)
Number of subjects: 87
Study 17553226 — intervention group
Group type: COMPARATOR
Intervention: Standard PCR
Number of subjects: 87
Study 14998784 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA ingestion during and after resistance exercise
Number of subjects: 7
Study 14998784 — intervention group
Group type: COMPARATOR
Intervention: Placebo ingestion during and after resistance exercise
Number of subjects: 7
Study 11464450 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprosartan (400-800 mg) alone or in combination with hydrochlorothiazide (HCTZ)
Number of subjects: 706
Study 9513875 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenate 90
Number of subjects: 100
Study 9513875 — intervention group
Group type: EXPERIMENTAL
Intervention: Stuartnatal Plus
Number of subjects: 100
Study 9513875 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal 1/1
Number of subjects: 100
Study 9513875 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalins Rx
Number of subjects: 100
Study 9513875 — intervention group
Group type: COMPARATOR
Intervention: One-A-Day (without iron)
Number of subjects: 100
Study 7934950 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference-point landmarks
Number of subjects: 0
Study 7934950 — intervention group
Group type: COMPARATOR
Intervention: Perspective from which the text was written (route or survey)
Number of subjects: 0
Study 7934950 — intervention group
Group type: COMPARATOR
Intervention: Presence of a map at learning
Number of subjects: 0
Study 7934950 — intervention group
Group type: COMPARATOR
Intervention: Order of information in the text (linear or anchors-first)
Number of subjects: 0
Study 7934950 — intervention group
Group type: COMPARATOR
Intervention: Amount of information available while drawing sketch maps (full text, landmark names only, or no information)
Number of subjects: 0
Study 2923641 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group - instructed to find and read information relating directly to their patients' conditions
Number of subjects: 61
Study 2923641 — intervention group
Group type: COMPARATOR
Intervention: Control group - assigned required readings
Number of subjects: 61
Study 2923641 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 61
Study 2923641 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61
Study 2923641 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 61
Study 31794342 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mm-C (Filtek Z350 XT)
Number of subjects: 77
Study 31794342 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mm-B (Filtek Bulk Fill Posterior)
Number of subjects: 77
Study 31794342 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mm-C (Filtek Z350 XT)
Number of subjects: 77
Study 31794342 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mm-B (Filtek Bulk Fill Posterior)
Number of subjects: 77
Study 29095245 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooled Radiofrequency Ablation (CRFA)
Number of subjects: 151
Study 29095245 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular Steroid (IAS) injection
Number of subjects: 151
Study 28783858 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccine group (n=48)
Number of subjects: 91
Study 28783858 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (n=43)
Number of subjects: 91
Study 28783858 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 91
Study 26355928 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulodexide (Vessel Due F) treatment for 50 days
Number of subjects: 62
Study 26355928 — intervention group
Group type: COMPARATOR
Intervention: Control Group (no specific intervention mentioned)
Number of subjects: 62
Study 26355928 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulodexide (Vessel Due F) treatment
Number of subjects: 62
Study 23770234 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusive wrap
Number of subjects: 0
Study 23770234 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 21128816 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (M)
Number of subjects: 66
Study 21128816 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (M) plus Levothyroxine (L‐T₄)
Number of subjects: 66
Study 21128816 — intervention group
Group type: COMPARATOR
Intervention: Levothyroxine (L‐T₄)
Number of subjects: 66
Study 21128816 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 66
Study 17641893 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine 628 mg/m² b.i.d. plus paclitaxel 80 mg/m²
Number of subjects: 9
Study 17641893 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine 829 mg/m² b.i.d. plus paclitaxel 80 mg/m²
Number of subjects: 9
Study 15746509 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpharmacologic therapies
Number of subjects: 0
Study 15746509 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic therapies
Number of subjects: 0
Study 15746509 — intervention group
Group type: COMPARATOR
Intervention: Behavioral therapy
Number of subjects: 0
Study 12911181 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose albuterol (HDA)
Number of subjects: 108
Study 12911181 — intervention group
Group type: COMPARATOR
Intervention: Circulaire nebulizer (C-Neb)
Number of subjects: 108
Study 10232855 — intervention group
Group type: EXPERIMENTAL
Intervention: MART (Muscular Awareness Relaxation Training)
Number of subjects: 23
Study 10232855 — intervention group
Group type: COMPARATOR
Intervention: TENS (Transcutaneous Electrical Neural Stimulation)
Number of subjects: 23
Study 10232855 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 23
Study 8546472 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (400 mg UFT therapy daily for 10 days)
Number of subjects: 55
Study 8546472 — intervention group
Group type: COMPARATOR
Intervention: No preoperative chemotherapy
Number of subjects: 55
Study 2070704 — intervention group
Group type: EXPERIMENTAL
Intervention: Maalox TC (three tablets four times daily)
Number of subjects: 79
Study 2070704 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (150 mg twice daily)
Number of subjects: 79
Study 2070704 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 79
Study 2070704 — intervention group
Group type: EXPERIMENTAL
Intervention: Maalox TC
Number of subjects: 79
Study 6841505 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading remediation emphasizing phonetic decoding
Number of subjects: 61
Study 6841505 — intervention group
Group type: COMPARATOR
Intervention: Control group (instruction in other subjects)
Number of subjects: 61
Study 31393353 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy with cognitive-behavioral therapy (MTCBP) for 12 weeks
Number of subjects: 155
Study 31393353 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 155
Study 31393353 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy with cognitive-behavioral therapy (MTCBP)
Number of subjects: 155
Study 30334434 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of oral probiotics, dosage and duration not specified
Number of subjects: 0
Study 27736051 — intervention group
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (2,400 mg/d)
Number of subjects: 35
Study 27736051 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus cognitive-behavioral therapy for SUD
Number of subjects: 35
Study 24420987 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sildenafil
Number of subjects: 47
Study 24420987 — intervention group
Group type: COMPARATOR
Intervention: Inhaled iloprost
Number of subjects: 47
Study 22404182 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide + dexamethasone (Thal-Dex)
Number of subjects: 131
Study 22404182 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib + dexamethasone (Bort-Dex)
Number of subjects: 131
Study 20642198 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management education (contract to adopt behavior, workbook, weekly reinforcements for 12 weeks, frequent follow-up visits)
Number of subjects: 90
Study 20642198 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management education
Number of subjects: 90
Study 20642198 — intervention group
Group type: COMPARATOR
Intervention: Asthma brochures and social support (control group)
Number of subjects: 90
Study 17661935 — intervention group
Group type: EXPERIMENTAL
Intervention: HA gel
Number of subjects: 15
Study 17661935 — intervention group
Group type: COMPARATOR
Intervention: hylan B plus gel
Number of subjects: 15
Study 17823136 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent pacemaker (P group, n = 30)
Number of subjects: 60
Study 17823136 — intervention group
Group type: COMPARATOR
Intervention: No pacing (NP group, n = 30)
Number of subjects: 60
Study 14738022 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ascending uterine artery ligation
Number of subjects: 70
Study 14738022 — intervention group
Group type: COMPARATOR
Intervention: Tourniquet use (Control)
Number of subjects: 70
Study 10718074 — intervention group
Group type: COMPARATOR
Intervention: Control + caffeine (Cc)
Number of subjects: 40
Study 10718074 — intervention group
Group type: COMPARATOR
Intervention: Control + placebo (Cp)
Number of subjects: 40
Study 10718074 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep deprived + caffeine (SDc)
Number of subjects: 40
Study 10718074 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep deprived + placebo (SDp)
Number of subjects: 40
Study 9196163 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH 2 mg plus 1 mg on day 4
Number of subjects: 150
Study 9196163 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH 1 mg
Number of subjects: 150
Study 9196163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 1546123 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (450 mg/day, reduced to 300 mg/day after 4 weeks if required)
Number of subjects: 184
Study 1546123 — intervention group
Group type: COMPARATOR
Intervention: Amineptine (200 mg/day, reduced to 100 mg/day after 4 weeks if required)
Number of subjects: 184
Study 1546123 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 184
Study 1546123 — intervention group
Group type: COMPARATOR
Intervention: Amineptine
Number of subjects: 184
Study 2864663 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 15
Study 2864663 — intervention group
Group type: COMPARATOR
Intervention: Intensive antacid and thrombin
Number of subjects: 15
Study 31072304 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants in the RCT
Number of subjects: 0
Study 31072304 — intervention group
Group type: COMPARATOR
Intervention: Non-participants
Number of subjects: 0
Study 31072304 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants (BMQ)
Number of subjects: 0
Study 31072304 — intervention group
Group type: COMPARATOR
Intervention: Non-participants (BMQ)
Number of subjects: 0
Study 29210902 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 40
Study 29210902 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 40
Study 26289613 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth intervention (monthly teleassistance)
Number of subjects: 0
Study 26289613 — intervention group
Group type: COMPARATOR
Intervention: Traditional care
Number of subjects: 0
Study 24767806 — intervention group
Group type: EXPERIMENTAL
Intervention: Jaw relaxation for 20 minutes before dressing changes
Number of subjects: 100
Study 24767806 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 100
Study 22336748 — intervention group
Group type: COMPARATOR
Intervention: Group CBT
Number of subjects: 140
Study 22336748 — intervention group
Group type: COMPARATOR
Intervention: Self-help CBT
Number of subjects: 140
Study 22336748 — intervention group
Group type: EXPERIMENTAL
Intervention: No Treatment Control (NTC)
Number of subjects: 140
Study 20578091 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial radiation protection board (TRPB)
Number of subjects: 106
Study 20578091 — intervention group
Group type: COMPARATOR
Intervention: Standard lead apron and shielding without TRPB
Number of subjects: 106
Study 19186349 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir (R)
Number of subjects: 26
Study 19186349 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir with CVH (R+, CVH+)
Number of subjects: 26
Study 19186349 — intervention group
Group type: COMPARATOR
Intervention: No Ritonavir (no R)
Number of subjects: 26
Study 15927063 — intervention group
Group type: EXPERIMENTAL
Intervention: Single inhalation of hyaluronic acid
Number of subjects: 12
Study 15927063 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline desmosines in plasma and urine
Number of subjects: 12
Study 15927063 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary desmosine levels
Number of subjects: 12
Study 15927063 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen fragments in plasma
Number of subjects: 12
Study 15927063 — intervention group
Group type: EXPERIMENTAL
Intervention: JM403 in urine
Number of subjects: 12
Study 12446160 — intervention group
Group type: EXPERIMENTAL
Intervention: Assistive loading
Number of subjects: 11
Study 12446160 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive loading
Number of subjects: 11
Study 12446160 — intervention group
Group type: COMPARATOR
Intervention: Free loading
Number of subjects: 11
Study 12446160 — intervention group
Group type: COMPARATOR
Intervention: No loading
Number of subjects: 11
Study 10340882 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-Conservation Therapy (BCT)
Number of subjects: 363
Study 10340882 — intervention group
Group type: COMPARATOR
Intervention: Mastectomy
Number of subjects: 363
Study 7488812 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for 6 months (protocol C)
Number of subjects: 184
Study 7488812 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for 2 months (protocol B)
Number of subjects: 184
Study 7488812 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for 3 months (protocol A)
Number of subjects: 184
Study 1928875 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal (AC) administered 15 minutes after acetaminophen
Number of subjects: 10
Study 1928875 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal (AC) administered 30 minutes after acetaminophen
Number of subjects: 10
Study 1928875 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal (AC) administered 120 minutes after acetaminophen
Number of subjects: 10
Study 1928875 — intervention group
Group type: COMPARATOR
Intervention: Control phase (no AC)
Number of subjects: 10
Study 6869761 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate infusion
Number of subjects: 3
Study 6869761 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl infusion
Number of subjects: 3
Study 6869761 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid infusion of etomidate
Number of subjects: 3
Study 6869761 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone bolus injection
Number of subjects: 3
Study 6869761 — intervention group
Group type: EXPERIMENTAL
Intervention: All techniques (etomidate, fentanyl, thiopentone)
Number of subjects: 3
Study 31623894 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (loading dose 1 g over 10 min then infusion of 1 g over 8 h)
Number of subjects: 12737
Study 31623894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12737
Study 30028656 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 531
Study 30028656 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine or pemetrexed without cisplatin
Number of subjects: 531
Study 27183545 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide (FAc) 0.5 µg/day
Number of subjects: 0
Study 27183545 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide (FAc) 0.2 µg/day
Number of subjects: 0
Study 27183545 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 0
Study 24346280 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib administered 1 h after a low-fat meal
Number of subjects: 25
Study 24346280 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib administered 1 h after a high-fat meal
Number of subjects: 25
Study 24346280 — intervention group
Group type: COMPARATOR
Intervention: Lapatinib administered 1 h before a low-fat meal
Number of subjects: 25
Study 22041970 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rehydration solution (ORS) group
Number of subjects: 300
Study 22041970 — intervention group
Group type: COMPARATOR
Intervention: Fasting group
Number of subjects: 300
Study 19474284 — intervention group
Group type: EXPERIMENTAL
Intervention: Random PTF (n = 620)
Number of subjects: 806
Study 19474284 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched PTF (n = 86)
Number of subjects: 806
Study 19474284 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor-specific blood transfusion (DST) (n = 100)
Number of subjects: 806
Study 19474284 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-immunized female renal transplant recipients who did not receive a PTF)
Number of subjects: 806
Study 16636870 — intervention group
Group type: EXPERIMENTAL
Intervention: Clazosentan 30 mg/h for 3 h
Number of subjects: 8
Study 16636870 — intervention group
Group type: EXPERIMENTAL
Intervention: Clazosentan 60 mg/h for 6 h
Number of subjects: 8
Study 16636870 — intervention group
Group type: EXPERIMENTAL
Intervention: Clazosentan 30 mg/h for 12 h
Number of subjects: 8
Study 16636870 — intervention group
Group type: EXPERIMENTAL
Intervention: Clazosentan 10 mg/h for 3 h
Number of subjects: 8
Study 16636870 — intervention group
Group type: EXPERIMENTAL
Intervention: Clazosentan infusion
Number of subjects: 8
Study 16636870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 16135178 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (400 microg/puff, twice daily)
Number of subjects: 30
Study 16135178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 14650463 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9860108 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone 120 mg/day
Number of subjects: 139
Study 9860108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study 9860108 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone 40 mg/day
Number of subjects: 139
Study 8636714 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha 2a (IFN) treatment
Number of subjects: 18
Study 8636714 — intervention group
Group type: COMPARATOR
Intervention: Observation only (Control)
Number of subjects: 18
Study 2483687 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate 125 mg daily infusions
Number of subjects: 173
Study 2483687 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate
Number of subjects: 173
Study 2483687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study 61439 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa ('Aldomet') treatment
Number of subjects: 242
Study 61439 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 242
Study 61439 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (treated and control)
Number of subjects: 242